Amneal (AMRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Amneal Pharmaceuticals (AMRX) reported $695.42 million in revenue for the quarter ended March 2025, representing a year-over-year increase of 5.5%. EPS of $0.21 for the same period compares to $0.14 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $714.78 million, representing a surprise of -2.71%. The company delivered an EPS surprise of +40.00%, with the consensus EPS estimate being $0.15.While investors scrutinize revenue and earnings changes year-over-year and how they compare ...